WALTHAM, Mass., Aug. 5, 2019 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Morrison, M.D., Chief Executive Officer of Syndax, will participate in a panel discussion

ATLANTA and NEW YORK, Aug. 5, 2019 /PRNewswire/ -- Formation Capital ("Formation") and Safanad Limited ("Safanad") announce the sale of the parent company of RHA Health Services, LLC ("RHA"), the comprehensive provider of services to individuals with intellectual and developmental disabilities ("I/DD"), behavioral health needs and substan

TEL AVIV, Israel, Aug. 5, 2019 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol, a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis, or NASH, today provides business update and repor

IRVINE, Calif., Aug. 5, 2019 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it will release second quarter 2019 financial and operating results on Thursday, August 8, 2019 after the close of the U.S. financial markets and will host a conference call and webcast that day at

HOLON, Israel, Aug. 5, 2019 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today reported financia

REHOVOT, Israel, Aug. 5, 2019 /PRNewswire/ -- CollPlant (NASDAQ: CLGN) (the "Company"), a regenerative medicine company, announced today that it is developing 3D bioprinted implants for regeneration of breast tissue and has successfully produced first prototypes. The implants will be comprised of CollPlant's proprietary type I recombinant human collagen and a

INDIANAPOLIS, Aug. 5, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Emgality® (galcanezumab-gnlm) met the primary and all key secondary outcomes in CONQUER, a Phase 3 study evaluating the efficacy and safety of Emgality in the preventive treatment of chronic and episodic migraine in patients with documented previous

NEW YORK, Aug. 5, 2019 /PRNewswire/ -- Renowned Johns Hopkins surgeon, researcher and policy expert Martin (Marty) Makary, MD, MPH, will serve FAIR Health as its Policy Advisor. In that role, Dr. Makary will help inform the research and policy-related initiatives of FAIR Health, a national, independent nonprofit

TEL AVIV, Israel, Aug. 5, 2019 /PRNewswire/ -- VGS - Vascular Graft Solutions Ltd. announced today it has received CE Mark Approval for the FRAME FR, a novel solution for repair and stabilization of high flow and aneurysmal arteriovenous fistulas in hemodialysis patients.

BETHESDA, Md., Aug. 5, 2019 /PRNewswire/ -- In the coming year, the nation's Community Health Centers will serve more people than ever with patient numbers projected to reach 29 million – that's one in 12 Americans, according to estimates from the National Association of Community Health Centers (NACHC).  The new numbers were released as communities acros